# CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

- Source: PR Newswire M&A
- Published: 2026-11-22T10:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/carsgen-presents-first-clinical-data-on-its-in-vivo-car-t-product-candidate-ct1182-302947651.html
- Canonical: https://groundlevelnews.com/story/carsgen-presents-first-clinical-data-on-its-in-vivo-car-t-product-cand-aeea9d/

SHANGHAI, Nov. 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces the clinical data from CT1182 (KJ-C2529), a CD19/CD20-targeting in vivo CAR T-cell product candidate developed on...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
